ADUS
Addus HomeCare Corporation
NasdaqGSUSDEQUITY
Healthcare
DELAYED
Last price
120.81
▲ 0.26 (0.22%)
MARKET · —
Price
Open
121.00
Prev close
120.55
Day high
121.95
Day low
120.04
Volume
231.25K
Market cap
$2.26B
P/E (TTM)
21.19
52W range
87.95 – 124.44
Trailing performance
Returnvs SPY
1W
+4.09%
+5.5%
1M
+7.94%
+4.2%
3M
+29.54%
+26.4%
6M
+4.62%
-6.5%
YTD
+12.50%
+0.2%
1Y
+5.19%
-14.8%
3Y
+29.33%
-44.8%
5Y
—
—
Price return only. Dividends are not reinvested, so total return on a dividend payer will be higher than shown.
Fundamentals
Market cap$2.26B
Enterprise value$2.22B
Revenue (TTM)$1.48B
Gross profit$477.75M
EBITDA$166.14M
Net income$105.31M
EPS (TTM)$5.70
Free cash flow$119.75M
Total cash$99.57M
Total debt$108.82M
Book value / share$62.77
Shares outstanding18.67M
Float17.75M
Short % of float7.78%
Dividend yield—
Beta (5Y)0.87
Valuation & profitability ratios
Trailing P/E21.19
Forward P/E16.07
PEG ratio1.10
Price / sales—
Price / book1.92
EV / revenue1.50
EV / EBITDA13.36
Gross margin32.36%
Operating margin10.32%
Profit margin7.13%
Return on equity9.71%
Return on assets6.52%
Debt / equity9.48
Current ratio1.69
Fourteen ratios including P/E, PEG, EV/EBITDA, margins and return on equity.
Financial statements
| Line item | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|
| Total revenue | $1.42B | $1.15B | $1.06B | $951.12M |
| Cost of revenue | $0 | $0 | $0 | $0 |
| Gross profit | $0 | $0 | $0 | $0 |
| R&D | — | — | — | — |
| SG&A | — | — | — | — |
| Operating income | — | — | — | — |
| Pre-tax income | — | — | — | — |
| Tax provision | $0 | $0 | $0 | $0 |
| Net income | $95.91M | $73.60M | $62.52M | $46.02M |
| EBIT | $0 | $0 | $0 | $0 |
| Line item | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|
| Cash & equivalents | — | — | — | — |
| Short-term investments | — | — | — | — |
| Net receivables | — | — | — | — |
| Inventory | — | — | — | — |
| Total current assets | — | — | — | — |
| Total assets | — | — | — | — |
| Total current liabilities | — | — | — | — |
| Long-term debt | — | — | — | — |
| Total liabilities | — | — | — | — |
| Retained earnings | — | — | — | — |
| Shareholder equity | — | — | — | — |
| Line item | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|
| Net income | $95.91M | $73.60M | $62.52M | $46.02M |
| Depreciation | — | — | — | — |
| Change in working capital | — | — | — | — |
| Operating cash flow | — | — | — | — |
| Capital expenditure | — | — | — | — |
| Investing cash flow | — | — | — | — |
| Dividends paid | — | — | — | — |
| Buybacks | — | — | — | — |
| Financing cash flow | — | — | — | — |
| Net change in cash | — | — | — | — |
Earnings
Reported vs expected · EPS
| Quarter | Est. | Actual | Surprise |
|---|---|---|---|
| Jun 2026 | 1.70 | 1.73 | +1.9% |
| Mar 2026 | 1.54 | 1.62 | +4.9% |
| Dec 2025 | 1.72 | 1.77 | +2.6% |
| Sep 2025 | 1.53 | 1.56 | +1.7% |
Forward consensus
| Period | EPS | Analysts | Revenue | Growth |
|---|---|---|---|---|
| Current quarter | 1.79 | 13 | $388.69M | +7.3% |
| Next quarter | 1.89 | 13 | $394.09M | +5.6% |
| Current year | 7.04 | 14 | $1.52B | +7.1% |
| Next year | 7.52 | 14 | $1.60B | +4.9% |
Analyst targets & ownership
Mean target$134.69
High target$155.00
Low target$96.00
Implied upside11.49%
Analyst count13
ConsensusBUY
Strong buy / Buy3 / 9
Hold1
Sell / Strong sell0 / 1
Held by insiders2.81%
Held by institutions107.99%
Institutions holding413
Price targets, consensus spread, insider and institutional ownership.
Insider net activity
Net shares
+57.33K
Net buying
Buy transactions
17
85.53K shares
Sell transactions
23
28.21K shares
Net transactions
+40
Buys less sells
Sell : buy shares
0.3 : 1
Mixed
Insider-held shares
514.59K
Total on file
Insider transactions
| Date | Insider | Action | Shares | Value | Held |
|---|---|---|---|---|---|
| Jun 22, 26 | DIXON HEATHER BRIANNE President |
SELL | 288 | $27.01K | Direct |
| Jun 10, 26 | WEAVER SUSAN T. Director |
STOCK | 1.45K | $0 | Direct |
| Jun 10, 26 | GORDON DARIN J. Director |
STOCK | 1.45K | $0 | Direct |
| Jun 10, 26 | RUSH JEAN Director |
STOCK | 1.45K | $0 | Direct |
| Jun 10, 26 | HILL MILBOURNE VERONICA Director |
STOCK | 1.45K | $0 | Direct |
| Jun 10, 26 | LOPEZ ESTEBAN Director |
STOCK | 1.45K | $0 | Direct |
| Jun 10, 26 | EARLEY MICHAEL M Director |
STOCK | 1.45K | $0 | Direct |
| Jun 10, 26 | FIRST MARK L Director |
STOCK | 1.45K | $0 | Direct |
| May 21, 26 | LOPEZ ESTEBAN Director |
SELL | 250 | $23.25K | Direct |
| May 19, 26 | LOPEZ ESTEBAN Director |
SELL | 250 | $23.25K | Direct |
| Apr 21, 26 | BLESSING CLIFF DONALD Officer |
SELL | 178 | $16.66K | Direct |
| Mar 2, 26 | RAINES MONICA Officer |
SELL | 224 | $22.88K | Direct |
| Feb 25, 26 | POFF BRIAN Chief Financial Officer |
SELL | 2.86K | $304.74K | Direct |
| Feb 25, 26 | GAFFNEY SEAN Officer |
SELL | 1.26K | $133.97K | Direct |
What this is, and what it is not
These are SEC Form 4 filings — officers, directors and 10% owners reporting their own trades in the company's stock. Filing is due within two business days of the transaction, so this lags reality by days, and the provider adds its own lag on top.
A sale is not automatically bearish. Executives sell on scheduled 10b5-1 plans, to cover tax on vesting equity, and to diversify. Purchases with cash are generally the more informative signal, and they are far rarer.
This does not include congressional or senate trading. That comes from STOCK Act disclosures filed with the Senate eFD system and the House Clerk, which this data source does not carry.
Officer and director trades in their own stock, straight from Form 4 filings.
Insider holders
| Name | Relation | Shares held | Latest |
|---|---|---|---|
ALLISON R DIRK |
Chief Executive Officer | 183.15K | Sale |
ANDERSON DARBY P |
Officer | 46.25K | Sale |
BICKHAM W BRADLEY |
President | 37.60K | Sale |
DIXON HEATHER BRIANNE |
President | 44.37K | Sale |
EARLEY MICHAEL M |
Director | 16.09K | Stock Award(Grant) |
FIRST MARK L |
Director | 15.07K | Stock Award(Grant) |
GAFFNEY SEAN |
Officer | 20.08K | Sale |
GORDON DARIN J. |
Director | 14.24K | Stock Award(Grant) |
POFF BRIAN |
Chief Financial Officer | 63.69K | Sale |
STEVENSON ROBERTSON JAMES |
Officer | 14.03K | Sale |
Moving averages & technicals
SMA 10
118.23
+2.18% from price
SMA 20
117.69
+2.65% from price
SMA 50
109.21
+10.62% from price
SMA 100
101.64
+18.87% from price
SMA 200
105.35
+14.68% from price
EMA 12
118.25
+2.17% from price
EMA 26
115.57
+4.54% from price
EMA 50
111.04
+8.80% from price
RSI (14)
64.1
Neutral
MACD (12,26,9)
2.68
Hist -0.24
ATR (14)
3.64
3.01% of price
Realised vol 30D
26.1%
Annualised
Bollinger upper
121.58
20, 2σ
Bollinger lower
113.80
20, 2σ
50 / 200 cross
Golden
109.21 vs 105.35
Trend bias
Above 200
+14.68%
Risk profile
Beta vs SPY
0.29
Less volatile than market
Correlation to SPY
0.13
Largely independent
Realised vol 30D
26.1%
Annualised
Market vol 1Y
12.9%
SPY, annualised
Max drawdown 1Y
-27.9%
Peak to trough
Max drawdown 5Y
-34.9%
Peak to trough
ATR 14
3.64
3.01% of price
Beta (reported)
0.87
5Y monthly, from filing
Unusual options activity
Nothing crossed the thresholds in the expiries we scanned.
That is the normal state — most contracts trade well inside their existing open interest.
That is the normal state — most contracts trade well inside their existing open interest.
Contracts trading at or above their open interest, ranked by notional and where the print landed.
Options analytics
Put / call volume
—
—
Put / call open interest
0.00
Positioning, not flow
Max pain
125.00
+3.5% from spot
ATM implied vol
50.8%
Nearest strike to spot
Skew (10% OTM)
—
—
Call volume
0
Contracts, this expiry
Put volume
0
Contracts, this expiry
Heaviest call OI
125.00
1 contracts
Heaviest put OI
—
—
Max pain is the strike at which the largest dollar value of open contracts expires worthless. It describes current positioning; it is not a forecast and it moves as open interest changes.
Put/call ratios, max pain, implied volatility skew and where open interest is concentrated.
Options chain
Calls
| Strike | Last | Bid | Ask | Vol | OI | IV |
|---|---|---|---|---|---|---|
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
Puts
| Strike | Last | Bid | Ask | Vol | OI | IV |
|---|---|---|---|---|---|---|
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
Every listed expiry, both sides of the book, with volume, open interest and implied volatility.
Headlines
Hims & Hers Health Stock Trades Below The Market On Revenue And Above It On Cash
Trefis · 2d ago
Following Honor Technology's AI Care Management Rollout Across Home Instead Franchises, New Report Analyzes Global Non-Medical Home Care Market to 2033
GlobeNewswire · 10d ago
Addus HomeCare (ADUS) Just Flashed Golden Cross Signal: Do You Buy?
Zacks · 10d ago
Addus HomeCare COO Heather Dixon Departs; Brad Bickham Appointed as 1-Year Interim
MT Newswires · 12d ago
Addus HomeCare Announces Departure of Heather Dixon and Return of Brad Bickham as Chief Operating Officer on an Interim Basis
Business Wire · 12d ago
ADUS vs. ELAN: Which Stock Is the Better Value Option?
Zacks · 16d ago
Are Medical Stocks Lagging Novavax (NVAX) This Year?
Zacks · 16d ago
Addus HomeCare Q2 Momentum Seen Continuing, RBC Says
MT Newswires · 17d ago
PRIVATE STRATEGY · BY QUALIFICATION
The same data. A different seat.
The research you are reading is the input layer for a discretionary options program we run for a small number of qualified investors. Minimum $1,000,000.